Protocol summary

Study aim
Determining the effect of intravenous atropine and ephedrine in preventing arterial hypotension or bradycardia in patients who underwent spinal anesthesia.
Design
A clinical trial with a control group with randomized double-blind parallel groups in phase 3 on 156 patients, all patients who meet the inclusion criteria will be randomly divided into three groups using randomization software until the required sample size is completed.
Settings and conduct
This study will be conducted in Shahid Madani Hospital of Karaj.. Before starting spinal anesthesia and drug injection, as well as during surgery, blood pressure and heart rate will be monitored by NIBP method. Candidate patients to participate in the study will have a systolic blood pressure of 100 to 140 and will be placed in groups A and B to receive medicine.Ephedrine 0.15 mg/kg and atropine 0.01 mg/kg immediately before B Spinal anesthesia will be injected separately for the patients of the groups. Distilled water will be used in the control group.
Participants/Inclusion and exclusion criteria
Participants:Surgical candidates aged 18 to 60 years who are undergoing spinal anesthesia. Inclusion criteria include absence of arterial hypertension, absence of arrhythmia and no bradycardia or tachycardia. The exclusion criteria include: Taking beta blockers or calcium channel blockers for any reason, taking cardiac drugs and blood pressure drugs, primary systolic blood pressure more than 140 mmHg, tachycardia HR>100 before anesthetic injection, presence of ischemic heart disease, valvular disease Heart disease, hyperthyroidism, sensitivity to ephedrine and atropine, bleeding during surgery is more than 10%.
Intervention groups
Group A (ephedrine recipient) and B group (atropine recipient) and Group C (control or recipient of distilled water)
Main outcome variables
arterial blood pressure, heart rate, atropine, ephedrine

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20241102063564N1
Registration date: 2024-11-28, 1403/09/08
Registration timing: prospective

Last update: 2024-11-28, 1403/09/08
Update count: 0
Registration date
2024-11-28, 1403/09/08
Registrant information
Name
Maryam Ezati
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 4471 7099
Email address
ezati.maryam02@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-12-21, 1403/10/01
Expected recruitment end date
2025-04-21, 1404/02/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of the effect of intravenous ephedrine and atropine in the prevention of arterialhypotension and bradycardia after spinal anesthesia parallel clinicaltrial
Public title
Comparison of the effect of intravenous ephedrine and atropine in the prevention of arterialhypotension and bradycardia after spinal anesthesia parallel clinicaltrial
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
People aged 18 to 60 years absence of arterial hypertension absence of arrhythmia absence of bradycardia and tachycardia.
Exclusion criteria:
Taking beta blockers or calcium channel blockers for any reason taking cardiac drugs and blood pressure drugs primary systolic blood pressure more than 140 mmHg tachycardia HR>100 before anesthetic injection presence of ischemic heart disease Heart valve disease hyperthyroidism sensitivity to ephedrine or atropine bleeding during surgery is more than 10%
Age
From 18 years old to 60 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Outcome assessor
Sample size
Target sample size: 156
Randomization (investigator's opinion)
Randomized
Randomization description
All patients who meet the criteria for entering the study were randomized into three blocks: ephedrine, atropine and control. Divided in the form of simple random probability sampling to complete the required sample volume, they will be divided into three groups And they will be placed in three groups A (ephedrine recipient), B group (atropine recipient) and C group (control).
Blinding (investigator's opinion)
Double blinded
Blinding description
The study will be double-blind, the patient and the anesthesiologist who is the patient's caregiver and nurse, and taking notes Blood pressure and heart rate are their responsibility, they will not know about the type of injectable drugs and placebo
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Alborz University of Medical Sciences
Street address
Alborz University of Medical Sciences, Building of the Vice Chancellor for Research and Technology, Safarian Street, 45 Meter Golshahr, Karaj, Iran.
City
Karaj
Province
Alborz
Postal code
۳۱۹۸۷۶۴۶۵۳
Approval date
2024-10-28, 1403/08/07
Ethics committee reference number
IR.ABZUMS.REC.1403.196

Health conditions studied

1

Description of health condition studied
arterial hypotension
ICD-10 code
I95.8
ICD-10 code description
Other hypotension

Primary outcomes

1

Description
arterial hypotension
Timepoint
Patients' blood pressure will be measured at baseline before spinal anesthesia and drug injection, then every 1 minute to 10 minutes, and then every 5 minutes to 45 minutes after drug injection.
Method of measurement
Blood pressure monitoring of patients will be by NIBP (Non Invasive Blood Pressure) method

2

Description
bradycardia
Timepoint
Patients' heart rate will be measured at baseline before spinal anesthesia and drug injection, then every 1 minute to 10 minutes, and then every 5 minutes to 45 minutes after drug injection.
Method of measurement
heart rate monitoring of patients will be by NIBP (Non Invasive Blood Pressure) method

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group A: Ephedrine 0.15 mg per kg will be injected immediately before spinal anesthesia for group A patients. The amount of injectable ephedrine per shift will be 0.15 mg/kg per shift until the systolic blood pressure and HR reach the patient's baseline figure. It should be noted that the same drug brand will be used for all patients. During the operation, 500 cc of normal saline will be injected per hour of surgery.Patients' blood pressure and heart rate will be measured at baseline before spinal anesthesia and drug injection, then every 1 minute to 10 minutes, and then every 5 minutes to 45 minutes after drug injection. If the patient's blood pressure drops by more than 20% compared to the baseline value, in the treatment groups, in addition to receiving medication, normal saline will be injected for free.
Category
Prevention

2

Description
Intervention group B: Atropine 0.01 mg per kg will be injected immediately before spinal anesthesia for group B patients. The amount of injectable atropine 0.01 mg/kg per shift will be prescribed until the systolic blood pressure and HR reach the patient's baseline figure. It should be noted that the same drug brand will be used for all patients. During the operation, 500 cc of normal saline will be injected per hour of surgery.Patients' blood pressure and heart rate will be measured at baseline before spinal anesthesia and drug injection, then every 1 minute to 10 minutes, and then every 5 minutes to 45 minutes after drug injection. If the patient's blood pressure drops by more than 20% compared to the baseline value, in the treatment groups, in addition to receiving medication, normal saline will be injected for free
Category
Prevention

3

Description
Control group: Distilled water will be used in the control group, and in case of any hemodynamic disorder, routine treatment or scientific standard treatment will be started for the patient so that the patient will not be harmed during the research process. During the operation, 500 cc of normal saline will be injected per hour of surgery. became. Patients' blood pressure and heart rate will be measured at baseline before spinal anesthesia and drug injection, then every 1 minute to 10 minutes, and then every 5 minutes to 45 minutes after drug injection.In the control group, if the patient's blood pressure decreased by more than 20% compared to the baseline, she will receive medicine according to the routine treatment of the hospital.
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Karaj Shahid Madani Hospital
Full name of responsible person
Dr. Seyed Mohsen Pouriagoubi
Street address
Madani Hospital, Shahid Madani Square, Mahaan Boulevard, Jahanshahr, Karaj, Iran
City
Karaj
Province
Alborz
Postal code
3143744693
Phone
+98 26 3442 7001
Email
Ezati.maryam02@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Karaj University of Medical Sciences
Full name of responsible person
Mrs. Dr. Lotfi
Street address
Alborz University of Medical Sciences, Building of the Vice Chancellor for Research and Technology, Safarian Street, 45 Meter Golshahr, Karaj, Iran.
City
Karaj
Province
Alborz
Postal code
۳۱۹۸۷۶۴۶۵۳
Phone
+98 26 3464 3705
Email
Ezati.maryam02@gmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Karaj University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Karaj University of Medical Sciences
Full name of responsible person
Dr. Seyed Mohsen Pouriagoubi
Position
associate professor
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Madani Hospital, Shahid Madani Square, Mahaan Boulevard, Jahanshahr, Karaj, Iran
City
Karaj
Province
Alborz
Postal code
3143744693
Phone
+98 26 3443 4700
Email
Ezati.maryam02@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Karaj University of Medical Sciences
Full name of responsible person
Dr. Seyed Mohsen Pouriagoubi
Position
associate professor
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Madani Hospital, Shahid Madani Square, Mahaan Boulevard, Jahanshahr, Karaj, Iran
City
Karaj
Province
Alborz
Postal code
3143744693
Phone
+98 26 3443 4700
Email
Ezati.maryam02@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Karaj University of Medical Sciences
Full name of responsible person
Dr. Seyed Mohsen Pouriagoubi
Position
associate professor
Latest degree
Specialist
Other areas of specialty/work
Anesthesiology
Street address
Madani Hospital, Shahid Madani Square, Mahaan Boulevard, Jahanshahr, Karaj, Iran.
City
Karaj
Province
Alborz
Postal code
3143744693
Phone
+98 26 3443 4700
Email
Ezati.maryam02@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
No final decision has been made yet and no further information is available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...